JETEMA, Co., Ltd.

KOSDAQ:A216080 Stock Report

Market Cap: ₩277.3b

JETEMA Valuation

Is A216080 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A216080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A216080 (₩15500) is trading above our estimate of fair value (₩3106.44)

Significantly Below Fair Value: A216080 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A216080?

Key metric: As A216080 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A216080. This is calculated by dividing A216080's market cap by their current earnings.
What is A216080's PE Ratio?
PE Ratio13.5x
Earnings₩20.55b
Market Cap₩277.33b

Price to Earnings Ratio vs Peers

How does A216080's PE Ratio compare to its peers?

The above table shows the PE ratio for A216080 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.2x
A041960 Komipharm International
23.6xn/a₩267.4b
A003220 Daewon Pharmaceutical
19.1x45.6%₩305.4b
A058820 CMG Pharmaceutical
84.8xn/a₩245.6b
A001630 Chong Kun Dang Holdings
5.5x-57.7%₩227.1b
A216080 JETEMA
13.5x-55.8%₩277.3b

Price-To-Earnings vs Peers: A216080 is good value based on its Price-To-Earnings Ratio (13.5x) compared to the peer average (33.2x).

Price to Earnings Ratio vs Industry

How does A216080's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$45.16m
No more companies available in this PE range
A216080 13.5xIndustry Avg. 13.0xNo. of Companies8PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A216080 is expensive based on its Price-To-Earnings Ratio (13.5x) compared to the KR Pharmaceuticals industry average (12x).

Price to Earnings Ratio vs Fair Ratio

What is A216080's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A216080 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.5x
Fair PE Ratio5.4x

Price-To-Earnings vs Fair Ratio: A216080 is expensive based on its Price-To-Earnings Ratio (13.5x) compared to the estimated Fair Price-To-Earnings Ratio (5.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 09:48
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JETEMA, Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyun Jeong SonYuanta Securities Korea Co., Ltd.